S.Korea’s Lunit installs breast cancer AI diagnostic tools at 200 US hospitals

Q: How long will it take to read this news story?

The story "S.Korea’s Lunit installs breast cancer AI diagnostic tools at 200 US hospitals" has 351 words across 18 sentences, which will take approximately 2 - 3 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "S.Korea’s Lunit installs breast cancer AI diagnostic tools at 200 US hospitals" was covered 14 hours ago by Korea Economic Daily, a news publisher based in South Korea.

Q: How trustworthy is 'Korea Economic Daily' news outlet?

Korea Economic Daily is a fully independent (privately-owned) news outlet established in 1964 that covers mostly economy news. The outlet is headquartered in South Korea and publishes an average of 8 news stories per day. It's most recent story was published 7 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #28865486</li><li>URL: https://articulation360.beamstart.com/news/skoreas-lunit-installs-breast-cancer-1747719446547</li></ul>

Korea Economic Daily Logo Korea Economic Daily 14h ago

S.Korea’s Lunit installs breast cancer AI diagnostic tools at 200 US hospitals - Korea Economic Daily

Quick Summary:

Lunit Inc., a South Korean AI-powered cancer diagnostics company, said on Monday that more than 200 healthcare institutions across the US have now adopted its breast cancer diagnostic equipment – a key milestone one year after acquiring New Zealand-based breast imaging analytics firm Volpara Health Technologies Ltd.

At the Radiological Society of North America (RSNA) 2024 conference in December, the company unveiled Lunit Insight Risk – a tool designed to predict the likelihood of developing breast cancer within one to five years.

In 2023, Lunit obtained approval for its AI cancer diagnosis programs – Lunit Insight DBT, Lunit Insight MMG and AI triage device Lunit Insight Triage – from the US Food and Drug Administration (FDA).“Our differentiated AI technology is being recognized in the US market for its ability to detect suspicious lesions with precision,” said a Lunit official.